antibody-drug conjugates for her2-low disease: 2023 ku breast cancer year in review
Published 1 year ago • 97 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
25:20
her2 low breast cancer a new therapeutic subtype | 2023 ku breast cancer year in review conference
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
25:46
antibody drug conjugates present and future applications in breast cancer
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
8:15
her2 positive, negative or low? breast cancer updates in 2023
-
53:15
will new antibody drug conjugates cure bladder cancer?
-
11:25
podcast 293: her2-“low” breast cancer and its reponse to an antibody-drug conjugate
-
2:23
preserving fertility, and genomic assays in breast cancer: 2023 ku breast cancer year in review
-
2:24
hot topics for case discussion in breast cancer: 2023 ku breast cancer year in review
-
1:45
antibody drug conjugates in metastatic breast cancer | sramila aithal, md | esmo22 pennsylvania
-
1:00:01
her2 mbc | 2023 best of breast conference
-
3:42
antibody drug conjugates in metastatic breast cancer | anthony elias, md | esmo22 colorado
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
18:25
emerging antibody-drug conjugates in breast cancer: an expert analysis of promising therapies
-
2:40
emergence of antibody-drug conjugates in metastatic breast cancer: 2022 esmo florida
-
11:57
antibody-drug conjugates used in breast cancers | oncology 2022
-
5:16
treatment options for her2-low breast cancer: all you need to know